Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
Servier, Pfizer In and Cellectis announced that preliminary results from two phase 1 trials with UCART19, the allogeneic anti-CD19 CAR...